Download CV
... Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Traystman RJ, Robinson MB, Britton P, Lu M, Tortella FC, Wozniak K, Yudkoff M, Jackson PF. “An inhibitor of NAAG hydrolysis prevents ischemic glutamate release and provides neuroprotection.” Nature Medicine, 1999, 5:1396-1402 Thomas AJ, Olkowski JH, Vornov ...
... Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Traystman RJ, Robinson MB, Britton P, Lu M, Tortella FC, Wozniak K, Yudkoff M, Jackson PF. “An inhibitor of NAAG hydrolysis prevents ischemic glutamate release and provides neuroprotection.” Nature Medicine, 1999, 5:1396-1402 Thomas AJ, Olkowski JH, Vornov ...
Hepatotoxicity in rats induced by aqueous extract of
... standard. Most importantly, RUCAM is a means of assigning points for clinical, biochemical, and serologic features as well as searching for nondrug causes. There is an update of RUCAM as a development of diagnostic methods and sensitive biomarkers, which made a major step forward to facilitate causa ...
... standard. Most importantly, RUCAM is a means of assigning points for clinical, biochemical, and serologic features as well as searching for nondrug causes. There is an update of RUCAM as a development of diagnostic methods and sensitive biomarkers, which made a major step forward to facilitate causa ...
In Vivo Criteria To Differentiate Monoamine Reuptake Inhibitors from
... validity of these four criteria for in vivo differentiation of monoamine reuptake inhibitors from releasing drugs. Although there are in vitro tests available, because the pharmacological profile of compounds can be altered by metabolism, it is important to perform in vivo tests. In order to achieve ...
... validity of these four criteria for in vivo differentiation of monoamine reuptake inhibitors from releasing drugs. Although there are in vitro tests available, because the pharmacological profile of compounds can be altered by metabolism, it is important to perform in vivo tests. In order to achieve ...
Evaluation of different mycobacterial species for drug discovery and
... used for anti-Tb drug high-throughput screening (HTS), and to use this model to identify a novel candidate anti-tubercular drug and its cognate cellular target. A sensitive growth inhibition assay was set up with a GFP-labelled Tb vaccine strain, M. bovis BCG, using standard first and second line an ...
... used for anti-Tb drug high-throughput screening (HTS), and to use this model to identify a novel candidate anti-tubercular drug and its cognate cellular target. A sensitive growth inhibition assay was set up with a GFP-labelled Tb vaccine strain, M. bovis BCG, using standard first and second line an ...
as a PDF
... potent and selective inhibitors against this CYP isoform are indispensible tools. With use of recombinant CYP2J2 enzyme, screening of substrate and inhibitor of this CYP isoform can be performed, because specific substrate can be useful for profiling CYP2J2 inhibition of drug candidates in vitro in ...
... potent and selective inhibitors against this CYP isoform are indispensible tools. With use of recombinant CYP2J2 enzyme, screening of substrate and inhibitor of this CYP isoform can be performed, because specific substrate can be useful for profiling CYP2J2 inhibition of drug candidates in vitro in ...
PREZISTA® (darunavir) oral suspension PREZISTA® (darunavir
... patients 3 years of age and older [see Use in Specific Populations (8.4)]. The indication for treatment-experienced pediatric patients 3 to less than 18 years of age is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two open-label Phase 2 trials in antiretroviral treatment-ex ...
... patients 3 years of age and older [see Use in Specific Populations (8.4)]. The indication for treatment-experienced pediatric patients 3 to less than 18 years of age is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two open-label Phase 2 trials in antiretroviral treatment-ex ...
the PDF
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
... Donepezil + memantine (ADS-8704, Arimenda; Adamas Pharmaceuticals), a once-daily fixed dose combination extended release formulation, is currently tested in Phase II clinical trials. In May 2012, the FDA approved Phase III studies in an end-of-Phase II meeting. First clinical results were presented ...
Pharmacokinetic Interaction Between Prasugrel and Ritonavir
... level 26 times that of observed without ritonavir, and the increase of midazolam’s Cmax to a level 6 times that observed without ritonavir. These results are in agreement with previous studies demonstrating that ritonavir is a very potent CYP3A inhibitor [11,18]. A previous study assessing the effec ...
... level 26 times that of observed without ritonavir, and the increase of midazolam’s Cmax to a level 6 times that observed without ritonavir. These results are in agreement with previous studies demonstrating that ritonavir is a very potent CYP3A inhibitor [11,18]. A previous study assessing the effec ...
Lopinavir/Ritonavir
... Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with low-dose ritonavir significantly improves the pharmacokinetic properties and hence the activity of lopinavir against HIV-1 protease. Coformulated lopinavir/ritonavir was developed for ease of administration ...
... Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with low-dose ritonavir significantly improves the pharmacokinetic properties and hence the activity of lopinavir against HIV-1 protease. Coformulated lopinavir/ritonavir was developed for ease of administration ...
Reyataz - Products - Bristol
... • Phenylketonuria: REYATAZ (atazanavir) oral powder contains phenylalanine which can be harmful to patients with phenylketonuria. (5.4) • Hepatotoxicity: Patients with hepatitis B or C infection are at risk of increased transaminases or hepatic decompensation. Monitor hepatic laboratory tests prio ...
... • Phenylketonuria: REYATAZ (atazanavir) oral powder contains phenylalanine which can be harmful to patients with phenylketonuria. (5.4) • Hepatotoxicity: Patients with hepatitis B or C infection are at risk of increased transaminases or hepatic decompensation. Monitor hepatic laboratory tests prio ...
BoNT_A Presentation UMass Dartmouth 081029
... BoNT serotypes exists (A-G), which differ significantly in amino acid sequence, protein substrates, and substrate cleavage sites ...
... BoNT serotypes exists (A-G), which differ significantly in amino acid sequence, protein substrates, and substrate cleavage sites ...
... ABSTRACT: In addition to its emerging immunomodulatory properties, theophylline is a bronchodilator and also decreases mean pulmonary arterial pressure in vivo. The mechanism of action of this drug remains controversial; adenosine antagonism, phosphodiesterase (PDE) inhibition and other actions have ...
Prescribing Information REYATAZ TM 150 mg REYATAZ TM 200 mg
... REYATAZ (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks durat ...
... REYATAZ (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks durat ...
HIV/AIDS Guidelines
... Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist .........K-17 Table 15a. Drug Interactions between PIs and Other Drugs .............................................K-19 Table 15b. Drug Interactions between NNRTIs and Other Drugs......................................K-30 ...
... Table 14. Drugs That Should Not Be Used with PIs, NNRTIs, or CCR5 Antagonist .........K-17 Table 15a. Drug Interactions between PIs and Other Drugs .............................................K-19 Table 15b. Drug Interactions between NNRTIs and Other Drugs......................................K-30 ...
5.02 atazanavir + cobicistat
... The market size estimates presented in the submission might not have been reasonable because: - The market for atazanavir/cobicistat FDC was projected based on two data points representing atazanavir use and an assumption regarding the change in market size that was not well justified. - The assumed ...
... The market size estimates presented in the submission might not have been reasonable because: - The market for atazanavir/cobicistat FDC was projected based on two data points representing atazanavir use and an assumption regarding the change in market size that was not well justified. - The assumed ...
Symposium Report Correlating Structure and Function of Drug
... Fig. 3. P450 secondary and tertiary structure. (A) Topological features of a microsomal P450 as illustrated by the Protein Data Bank:2NNI structure of human microsomal 2C8 colored from blue at the N-terminus to red at the Cterminus. The active site cavity is shown as a transparent surface. The bound ...
... Fig. 3. P450 secondary and tertiary structure. (A) Topological features of a microsomal P450 as illustrated by the Protein Data Bank:2NNI structure of human microsomal 2C8 colored from blue at the N-terminus to red at the Cterminus. The active site cavity is shown as a transparent surface. The bound ...
NIH Public Access - The Scripps Research Institute
... mammalian member. AS enzymes are characterized by a highly conserved region that is rich in serine, glycine, and alanine residues comprising approximately 130 amino acid residues. Despite sharing significant sequence homology, members of this enzyme class exhibit markedly different substrate specifi ...
... mammalian member. AS enzymes are characterized by a highly conserved region that is rich in serine, glycine, and alanine residues comprising approximately 130 amino acid residues. Despite sharing significant sequence homology, members of this enzyme class exhibit markedly different substrate specifi ...
4. post-exposure prophylaxis for hiv
... requirements to obtain information about drug resistance risk. Providing three drugs for post-exposure prophylaxis is also consistent with recommendations for ART, the standard for which is triple-combination therapy. Although the addition of a third drug increases the potential for drug-related tox ...
... requirements to obtain information about drug resistance risk. Providing three drugs for post-exposure prophylaxis is also consistent with recommendations for ART, the standard for which is triple-combination therapy. Although the addition of a third drug increases the potential for drug-related tox ...
Attachment: Product Information: Atazanavir
... Coadministration of a single 300mg dose of Reyataz and a 100mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state. Coadministratio ...
... Coadministration of a single 300mg dose of Reyataz and a 100mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24-hour concentration of atazanavir relative to the fasting state. Coadministratio ...
PREZISTA® - Janssen
... decreased susceptibility against 90% of 3309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir, showing that many viruses resistant to most HIV PIs remain susceptible to darunavir. Seven of the 9 darunavir-resistant virus ...
... decreased susceptibility against 90% of 3309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir, showing that many viruses resistant to most HIV PIs remain susceptible to darunavir. Seven of the 9 darunavir-resistant virus ...
Review Nucleotide prodrugs for HCV therapy
... boceprevir. Each of these compounds has completed Phase III clinical investigation and both have been shown to be efficacious in treating HCV infection when given in combination with SOC. However, each of these first generation protease inhibitors suffers from the lack of genotype coverage, undesire ...
... boceprevir. Each of these compounds has completed Phase III clinical investigation and both have been shown to be efficacious in treating HCV infection when given in combination with SOC. However, each of these first generation protease inhibitors suffers from the lack of genotype coverage, undesire ...
Contributions of CYP3A4, P-glycoprotein, and Serum Protein
... addition, severely ill AIDS patients demonstrated a significantly higher (⬃3-fold) dose-adjusted AUC of saquinavir compared with less ill patients (Kodjo et al., 1997). Increased serum AAG may in part account for these observations, because mice genetically engineered to express high levels of human ...
... addition, severely ill AIDS patients demonstrated a significantly higher (⬃3-fold) dose-adjusted AUC of saquinavir compared with less ill patients (Kodjo et al., 1997). Increased serum AAG may in part account for these observations, because mice genetically engineered to express high levels of human ...
DRUG INTERACTIONS WITH INTEGRASE INHIBITORS
... studies, raltegravir kinetics were measured in the presence of steady-state boosted or unboosted atazanavir. In the presence of chronic atazanavir 400 mg QD, single dose raltegravir 100 mg resulted in raltegravir AUC ↑ 72%, Cmax ↑ 53%, C12 ↑ 95% compared to raltegravir alone. In an open-label, rando ...
... studies, raltegravir kinetics were measured in the presence of steady-state boosted or unboosted atazanavir. In the presence of chronic atazanavir 400 mg QD, single dose raltegravir 100 mg resulted in raltegravir AUC ↑ 72%, Cmax ↑ 53%, C12 ↑ 95% compared to raltegravir alone. In an open-label, rando ...
Tybost - Gilead Sciences, Inc.
... who have an estimated creatinine clearance below 70 mL/min because dose adjustment of tenofovir DF is required below 50 mL/min and such dose adjustments have not been established for coadministration with TYBOST [see Dosage and Administration (2.2, 2.3)]. ...
... who have an estimated creatinine clearance below 70 mL/min because dose adjustment of tenofovir DF is required below 50 mL/min and such dose adjustments have not been established for coadministration with TYBOST [see Dosage and Administration (2.2, 2.3)]. ...
Reyataz ® (atazanavir) - Bristol
... Nephrolithiasis and Cholelithiasis: Cases of nephrolithiasis and/or cholelithiasis were reported during post-marketing surveillance in HIV-infected patients receiving atazanavir therapy. Some patients required hospitalization for additional management and some had complications. Because these events ...
... Nephrolithiasis and Cholelithiasis: Cases of nephrolithiasis and/or cholelithiasis were reported during post-marketing surveillance in HIV-infected patients receiving atazanavir therapy. Some patients required hospitalization for additional management and some had complications. Because these events ...
Discovery and development of HIV-protease inhibitors
Many major physiological processes depend on regulation of proteolytic enzyme activity and there can be dramatic consequences when equilibrium between an enzyme and its substrates is disturbed. In this prospective, the discovery of small-molecule ligands, like protease inhibitors, that can modulate catalytic activities has an enormous therapeutic effect. Hence, inhibition of the HIV protease is one of the most important approaches for the therapeutic intervention in HIV infection and their development is regarded as major success of structure-based drug design. They are highly effective against HIV and have, since the 1990s, been a key component of anti-retroviral therapies for HIV/AIDS.